OPTIMIZATION OF MENOPAUSAL HORMONE THERAPY-RELATED RISKS: THERAPY WITH TRANSDERMAL ESTROGENS ALONE OR IN COMBINATION WITH MICRONIZED PROGESTERONE. ADVANTAGES AGAINST METABOLIC RISKS AND ARTERIAL THROMBOSIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The correct choice of a treatment option for menopausal symptoms is of key value, by taking into account the broad spectrum of menopausal hormone therapy (MHT) drugs, including parenteral ones available in the arsenal of a modern-day physician. Objective. To consider the impact of therapy with transdermal estrogens alone or in combination with micronized progesterone on metabolic parameters and the incidence of arterial thrombosis and cholelithiasis in postmenopausal patients. Subject and methods. Proper-quality clinical and experimental studies published since 2002 on the safety of MHT for metabolic disorders, coronary heart disease, stroke, and cholelithiasis with focus on parental estradiol and m icronized progesterone were reviewed. Results. The studies given in the review show that the benefits and risks of MHT for metabolic disorders, coronary heart disease, and stroke are greatly different depending on the route of estradiol administration and the type of progestagen. The advantages of transdermal versus oral estrogens in increasing the risk of cholelithiasis are also of great importance for a population of postmenopausal women. Conclusion. The correct choice of a drug and its administration route during MHT is particularly important due to the expansion of time frames for this therapy in women having indications for this treatment.

Full Text

Restricted Access

About the authors

Svetlana Vladimirovna Yureneva

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
MD Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. de Villiers T.J., Pines A., Panay N., Gambacciani M., Archer D.F., Baber R.J. et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.
  2. Santen R.J., Allred D.C., Ardoin S.P., Archer D.F., Boyd N., Braunstein G.D. et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 2010; 95(7,Suppl.1): s1-66.
  3. North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause. 2012; 19(3): 257-71.
  4. Stuenkel C.A., Gass M.L., Manson J.E., Lobo R.A., Pal L., Rebar R.W., Hall J.E. A decade after the Women’s Health Initiative-the experts do agree. J. Clin. Endocrinol. Metab. 2012; 97(8): 2617-8.
  5. Canonico M., Fournier A., Carcaillon L., Olié V., Plu-Bureau G., Oger E. et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5.
  6. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 2008; 107(1): 103-11.
  7. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet. Gynecol. 2009; 113(1): 65-73.
  8. Racine A., Bijon A., Fournier A., Mesrine S., Clavel-Chapelon F., Carbonnel F., Boutron-Ruault M. C. Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. Can. Med. Assoc. J. 2013; 185(7): 555-61.
  9. Liu B., Beral V., Balkwill A., Green J., Sweetland S., Reeves G.; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. Br. Med. J. 2008; 337: a386.
  10. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P. et al. The metabolic syndrome and cardiovascular risk: a systematic review and metaanalysis. J. Am. Coll. Cardiol. 2010; 56(14): 1113-32.
  11. Modena M. G., Sismondi P., Mueck A. O., Kuttenn F., Lignières Bd., Verhaeghe J. et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005; 52(1): 1-10.
  12. L’Hermite M., Simoncini T., Fuller S., Genazzani A.R. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008; 60(3-4): 185-201.
  13. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010; 17(2): 242-55.
  14. Margolis K.L., Bonds D.E., Rodabough R.J., Tinker L., Phillips L.S., Allen C. et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004; 47(7): 1175-87.
  15. de Lauzon-Guillain B., Fournier A., Fabre A., Simon N., Mesrine S., Boutron-Ruault M.C. et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidémiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N) cohort. Diabetologia. 2009; 52(10): 2092-100.
  16. Harman S.M., Black D.M., Naftolin F., Brinton E.A., Budoff M.J., Cedars M.I. et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann. Intern. Med. 2014; 161(4): 249-60.
  17. Tremollieres F., Brincat M., Erel C. T., Gambacciani M., Lambrinoudaki I., Moen M.H. et al.; European Menopause and Andropause Society. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas. 2011; 69(2): 195-8.
  18. Mercuro G., Zoncu S., Piano D., Pilia I., Lao A., Melis G.B., Cherchi A. Estradiol-17 β reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am. J. Hypertens. 1998; 11(8,Pt1): 909-13.
  19. Yun B.H., Chon S.J., Lee Y.J., Han E.J., Cho S., Choi Y.S. et al. Association of metabolic syndrome with coronary atherosclerosis in non-diabetic postmenopausal women. Climacteric. 2015; 18(2): 284-9.
  20. Chedraui P., Escobar G.S., Pérez-López F.R., Palla G., Montt-Guevara M., Cecchi E. et al. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014; 77(4): 370-4.
  21. Løkkegaard E., Andreasen A.H., Jacobsen R.K., Nielsen L.H., Agger C., Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur. Heart J. 2008; 29(21): 2660-8.
  22. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68.
  23. Rossouw J.E., Manson J.E., Kaunitz A.M., Anderson G.L. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet. Gynecol. 2013; 121(1): 172-6.
  24. Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M. et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011; 123(11): 1243-62.
  25. Grodstein F., Manson J.E., Stampfer M.J., Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch. Intern. Med. 2008; 168(8): 861-6.
  26. Sare G.M., Gray L.J., Bath P.M. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 2008; 29(16): 2031-41.
  27. Renoux C., Dell’aniello S., Garbe E., Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. Br. Med. J. 2010; 340: c2519. doi: 10.1136/bmj.c2519.
  28. Lobo R.A., Clarkson T.B. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause. 2011; 18(2): 237-40.
  29. Carcaillon L., Alhenc-Gelas M., Bejot Y., Spaft C., Ducimetière P., Ritchie K. et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly. The Three-City Cohort Study. Arterioscler. Thromb. Vasc. Biol. 2011; 31(6): 1445-57.
  30. Portincasa P., Moschetta A., Palasciano G. Cholesterol gallstone disease. Lancet. 2006; 368(9531): 230-9.
  31. Ruhl C.E., Everhart J.E. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011; 140(2): 508-16.
  32. Heaton K.W., Braddon F.E., Mountford R.A., Hughes A.O., Emmett P.M. Symptomatic and silent gall stones in the community. Gut. 1991; 32(3): 316-20.
  33. Birkhauser M., Barlow D., Notelovitz M., Rees M. Health plan for the adult woman: management handbook. London, New York: Taylor&Francis; 2005.155p.
  34. Canonico M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause. 2014; 21(7): 753-62.
  35. Hodis H.N. ELITE - Does the trial outcome confirm or refute the timing hypothesis of hormone therapy? In: Presented at the14th World Congress on Menopause of the International Menopause Society, May 1-4, 2014, Cancun, Mexico.
  36. ACOG Practice Bulletin no. 141: management of menopausal symptoms. Obstet. Gynecol. 2014; 123(1): 202-16.
  37. http://www.menopause.org/docs/default-source/2015/2015-nams-hormone-therapy-after-age-65.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies